The World Generic Market Report 2012

Additional Information

Industry Issues
If the branded pharmaceutical industry was facing a patent cliff it is now teetering on the edge of it. Ironically, it is the world’s best selling drug, Lipitor, which exemplifies the trend. Despite still having patent protection, Pfizer has been unable to stem the tide of interest and pressure from a number of companies, Ranbaxy being chief amongst them. Despite pressure on prices in many markets, the generic sector continues to thrive with increased sales across the board in 2011. The maturity of the sector can also be seen in the size of the businesses: there are now 17 generic companies with revenues in excess of US$1 billion, 5 more than in 2008/09.

Company Assessments
Consolidation and collaboration continues to be the game plan for many in the sector. The rationalisation of the industry continues, but it is driven by different motivations. Certainly Teva’s acquisition of ratiopharm was of the traditional model of adding market and value, but the 2011 acquistion of Cephalon is altogether more interesting as it supports Teva’s long term movement to the development of branded drugs. But adding capability is equally important. Watson’s acquisition of Arrow group also provided a stake in Eden Biodesign which gives the company a platform for the biosimilars market.

Market Analysis
The generic market is experiencing two opposing trends driven by the global downturn. On one hand, the use of generics is increasing due to their cost-effectiveness and adoption has accelerated in markets where branded prescribing was dominant. On the other hand, the squeeze on government spending has not left generics untouched with many countries lowering generic prices through cuts in reimbursement rates or contract tendering with a resultant squeeze on margins.

All customers get the practical power of Espicom Interactive and at no additional cost! The interactive web-based version of The World Generic Market Report will rapidly identify the information you are looking for.

Export data and charts for inclusion in presentations
Address all questions across the product in your library
Share access with colleagues near and far with a flexible and cost-effective distribution licence. Please click on the link to contact Victoria McVeigh or telephone +44(0)1243 756027 for more details
Espicom’s Generic Drug Business Information; Espicom is the leading provider of business information on the global generic drug and emerging biosimilar markets. Throughout the year we publish a range of titles and reports which bring insight to the trends and developments which are affecting this major pharmaceutical sector. Please click on the title link below for more information.

World Generic Markets
A unique twice-monthly business publication which covers the latest company and market developments and reports on ANDA approvals, litigation, company performance and regulatory developments.

Global Biosimilars: A return to optimism? (January 2012)
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning
themselves for market entry.

Biosimilars Business Review
Biosimilar products are entering a new phase in their development but considerable technical and regulatory hurdles remain. Biosimilars Business Review is a quarterly business intelligence service that gets under the skin of this rapidly emerging sector to probe and analyse the issues it faces.

Generic Drugs: Global collaboration opportunities (Dec 2011) This insightful report from Espicom provides a key resource for the wide assessment of 160 medium-sized generic companies operating in 35 markets worldwide. Identify merger, acquisition and partner candidates in the rapidly changing and challenged global generics market.

More Information...
VOLUME I: COMPANY PROFILES
Industry Issues
Industry consolidation
The impact of the economic downturn
Regulation & confusion in the USA
European generic opportunities
Progress with biosimilars
Prospects for growth in key markets

Extensive company profiles covering
Financial performance
ANDAs and launched products
M&A activity and litigation

Companies covered
Actavis
Apotex
Aspen Pharmacare
Aurobindo
Cipla
Dr Reddy's Laboratories
Egis
Hospira
Impax Laboratories
Krka
Lannett
Lupin
Mylan
Par Pharmaceutical Companies
Perrigo
Ranbaxy Laboratories
Gedeon Richter
Sandoz
Sanofi
Sawai Pharmaceuticals
Simcere Pharmaceuticals
Stada Arzneimittel
Sun Pharmaceutical Industries
Teva Pharmaceutical Industries
Watson Pharmaceuticals
Wockhardt
Zydus Cadila

VOLUME II: COUNTRY PROFILES
Country market data covering
Key facts
Generic market value & 5-year forecast
SWOT analysis of each market
Patent protection/IP Issues
Pricing/reimbursement
The manufacturing sector

Markets covered
Australia
Brazil
Canada
France
Germany
Italy
Japan
Russia
Spain
Switzerland
UK
USA